# STAAR Surgical Company (STAA)

> Source: Nexqual · https://nexqual.com/STAA · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, STAAR Surgical Company (STAA), nexqual.com/STAA" · informational, not investment advice.

**Price:** USD 25.24 (+2.56% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 24.61 · day 24.61–25.52 · 52w 15.59–35.87 · market cap $1.27B · NGM

## Key facts
- Last four reported quarters (through Jul 3, 2026): revenue $340M, net income $3.8M (1.1% margin), free cash flow -$6.7M (SEC filings).
- Valuation: P/E 329.7x (avg 72.3x at the last 1 fiscal year-ends).
- Analysts: Hold (mean 2.73 on a 1–5 scale) (11 analysts), mean target USD 27.67 (range 19–37).
- Total return with dividends: 1Y -7.2% vs S&P 500 +14.8%; 5Y -78.7% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.17, revenue estimate $78.7M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: STAA paid no cash dividend in the last five years.
- Short interest: 15.37% of float (as of 2026-10-15), 3.8 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $230M | $239M | $322M | $314M | $239M | $340M |
| Gross profit | $179M | $223M | $253M | $240M | $182M | — |
| Operating income | $33.3M | $43.8M | $28.1M | -$12.6M | -$91.7M | $13.7M |
| Net income | $27.5M | $39.7M | $21.3M | -$20.2M | -$80.4M | $3.8M |
| EPS (diluted) | $0.56 | $0.80 | $0.43 | -$0.41 | -$1.62 | — |
| Free cash flow | $30.3M | $17.6M | -$3.6M | -$7.7M | -$40.0M | -$6.7M |
| Gross margin | 77.5% | 93.3% | 78.4% | 76.3% | 76.2% | — |
| Operating margin | 14.5% | 18.3% | 8.7% | -4.0% | -38.3% | 4.0% |
| Net margin | 11.9% | 16.6% | 6.6% | -6.4% | -33.6% | 1.1% |
| Revenue growth | +41.0% | +3.9% | +34.7% | -2.6% | -23.7% | — |
| Cash + short-term investments | $200M | $212M | $221M | $230M | $188M | — |
Fiscal years end Jan. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 3, 2026)
P/E 329.7x · P/S 3.7x · P/B 3.5x · FCF yield -0.53% · Earnings yield 0.30%
P/E at fiscal year-ends: Dec 2023 72.3x.

## Analysts
Consensus Hold (mean 2.73 on a 1–5 scale), 11 analysts; mean target USD 27.67 (low 19, high 37).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Stifel | Upgrade | Hold → Buy | $28 → $31 |
| 2026-09-22 | Jefferies | Target lowered | Buy | $28 → $23 |
| 2026-08-17 | Stifel | Target lowered | Hold | $31 → $28 |
| 2026-08-13 | UBS | Target lowered | Sell | $20 → $19 |
| 2026-08-13 | Jefferies | Target lowered | Buy | $29 → $28 |
| 2026-08-13 | Wedbush | Target lowered | Outperform | $40 → $37 |
| 2026-08-04 | Wedbush | Reiterated | Outperform | $40 |
| 2026-07-28 | UBS | Initiated | Sell | $20 |
| 2026-07-22 | Wedbush | Reiterated | Outperform | $40 |
| 2026-07-16 | Wedbush | Reiterated | Outperform | $40 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -7.2% | -78.7% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | -7.3% | -26.5% |
| Volatility (annualized) | 55.1% | 60.1% |
| Max drawdown | -42.8% (May 2026→Sep 2026) | -87.0% (Oct 2021→Feb 2025) |

## Dividends
STAA paid no cash dividend in the last five years.

## Short interest
3,696,106 shares sold short, 15.37% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 4,631,284 shares (-20.2%). Days to cover: 3.8 (short shares ÷ average daily volume).

## Peers (Medical Instruments & Supplies)
AZTA (Azenta, Inc.) USD 41.27 +1.58% · XRAY (DENTSPLY SIRONA Inc.) USD 9.61 +1.80% · LMAT (LeMaitre Vascular, Inc.) USD 85.27 +2.90% · WRBY (Warby Parker Inc.) USD 24.59 +0.65% · ATRC (AtriCure, Inc.) USD 62.48 +1.73% · PLSE (Pulse Biosciences, Inc) USD 55.48 +3.37%

## More
Full page: https://nexqual.com/STAA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.17 | $0.17 | +0.0% | $78.7M | 7 |
| Next quarter (ends 2026-12-31) | $0.09 | $0.08 | +20.0% | $68.4M | 7 |
| Current fiscal year (ends 2026-12-31) | $0.84 | $0.73 | +15.3% | $334.3M | 7 |
| Next fiscal year (ends 2027-12-31) | $1.11 | $0.99 | +12.4% | $360.6M | 7 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.25 | $0.23 | Beat +8.7% | — |
| — | Quarter ended Mar 31, 2026 | $0.29 | $0.08 | Beat +262.5% | — |
| — | Quarter ended Dec 31, 2025 | $0.01 | $0.17 | Miss −94.1% | — |
| — | Quarter ended Sep 30, 2025 | $0.47 | $0.28 | Beat +67.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).